Details of the Drug Combination

General Information of Drug Combination (ID: DCVN4PG)

Drug Combination Name

Acamprosate Valproic Acid

Indication

Disease Entry	Status	REF
Chronic myelogenous leukemia	Investigative	[1]

Component Drugs

Acamprosate DMO381I

Valproic Acid DMS49KH

Small molecular drug

2D MOL

3D MOL

High-throughput Screening Result

Testing Cell Line: KBM-7

Zero Interaction Potency (ZIP) Score: 23.93

Bliss Independence Score: 23.93

Loewe Additivity Score: 36.48

LHighest Single Agent (HSA) Score: 36.48

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)

Indication(s) of Acamprosate

Disease Entry	ICD 11	Status	REF
Alcohol dependence	6C40.2	Approved	[2]

Acamprosate Interacts with 1 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
Glutamate receptor AMPA (GRIA)	TTAN6JD	NOUNIPROTAC	Agonist	[5]
------------------------------------------------------------------------------------

Indication(s) of Valproic Acid

Disease Entry	ICD 11	Status	REF
Absence epilepsy	N.A.	Approved	[3]
Epilepsy	8A60-8A68	Approved	[3]
Glioblastoma	2A00	Approved	[3]
Coronavirus Disease 2019 (COVID-19)	1D6Y	Investigative	[4]
Neuroblastoma	2D11.2	Investigative	[3]

References

1	Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
2	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7106).
3	Valproic Acid FDA Label
4	Immunopharmacological management of COVID-19: Potential therapeutic role of valproic acid. Med Hypotheses. 2020 May 27;143:109891.
5	Predicting the effect of naltrexone and acamprosate in alcohol-dependent patients using genetic indicators. Addict Biol. 2009 Jul;14(3):328-37.